Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: A retrospective analysis of 90 patients

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Ehler, Johannes ^a   Koball, Sebastian ^a   Sauer, Martin ^a   Mitzner, Steffen ^a   Hickstein, Heiko ^a,b   Benecke, Reiner ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b KfH Dialysis Centre Wismar   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; DEMYELINATING DISEASE; DIAGNOSTIC TEST; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FAINTNESS; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; HYPOCALCEMIA; HYPOTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PATIENT IDENTIFICATION; PATIENT SAFETY; PLASMAPHERESIS; RETROSPECTIVE STUDY; SEPTIC SHOCK; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADVERSE EFFECTS; DEMYELINATING DISEASES; MIDDLE AGED; PATHOLOGY; PLASMA EXCHANGE; PROCEDURES; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DEMYELINATING DISEASES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PLASMA EXCHANGE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941894326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134583     Document Type: Article

References (47)

1. Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013 Sep 26; 13:128. doi: 10.1186/1471-2377-13-128 PMID: 24070256
2. Bohlega S. Epidemiology of MS. Mult Scler Relat Disord. 2014 Nov; 3(6):766-767.
3. McDonald WI. Relapse, remission, and progression in multiple sclerosis. N Engl J Med. 2000 Nov; 343 (20):1486-1487. PMID: 11078776
4. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007 Apr; 17(2):210-218. PMID: 17388952
5. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol. 2014 Dec; 262 Pt A:2-7. doi: 10.1016/j.expneurol.2013.12.003 PMID: 24342027
6. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006 Apr; 2(4):201-211. PMID: 16932551
7. Kantarci OH, Pirko I, Rodriguez M. Novel immunomodulatory approaches for the management of multiple sclerosis. Clin Pharmacol Ther. 2014 Jan; 95(1):32-44. doi: 10.1038/clpt.2013.196 PMID: 24173041
8. Sørensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014 Jun; 27 (3):246-259. doi: 10.1097/WCO.0000000000000096 PMID: 24759080
9. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005 Dec; 12(12):939-946. PMID: 16324087
10. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008 Oct; 255(10):1449-1463. doi: 10.1007/s00415-008-0061-1 PMID: 19005625
11. Bevan C, Gelfand JM. Therapeutic management of severe relapses in multiple sclerosis. Curr Treat Options Neurol. 2015 Apr; 17(4):345. doi: 10.1007/s11940-015-0345-6 PMID: 25794777
12. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004 Sep 28; 63(6):1081-1083. PMID: 15452303
13. Chhibber V, Weinstein R. Evidence-based review of therapeutic plasma exchange in neurological disorders. Semin Dial. 2012 Mar-Apr; 25(2):132-139. doi: 10.1111/j.1525-139X.2011.01023.x PMID: 22277020
14. Ehler J, Koball S, Sauer M, Hickstein H, Mitzner S, Benecke R, et al. Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome. Ther Apher Dial. 2014 Oct; 18(5):489-496. doi: 10.1111/1744-9987.12176 PMID: 24674271
15. Magaña SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011 Jul; 68(7):870-878. doi: 10.1001/archneurol.2011.34 PMID: 21403003
16. Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012 Aug; 126(2):103-108. doi: 10.1111/j.1600-0404.2011.01612.x PMID: 22050360
17. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec; 46(6):878-886. PMID: 10589540
18. Kaya E, Keklik M, Sencan M, Yilmaz M, Keskin A, Kiki I, et al. Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis. Transfus Apher Sci. 2013 Jun; 48 (3):349-352. doi: 10.1016/j.transci.2013.04.015 PMID: 23619327
19. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006 Jul; 63(7):930-935. PMID: 16831960
20. Bennetto L, Totham A, Healy P, Massey E, Scolding N. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol. 2004 Dec; 251 (12):1515-1521. PMID: 15645353
21. Habek M, Barun B, Puretić Z, Brinar VV. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial. 2010 Jun; 14(3):298-302. doi: 10.1111/j.1744-9987.2009.00794.x PMID: 20609182
22. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002 Jan; 58(1):143-146. PMID: 11781423
23. Meca-Lallana JE, Hernández-Clares R, León-Hernández A, Genovés Aleixandre A, Cacho Pérez M, Martín-Fernández JJ. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. Clin Ther. 2013 Apr; 35(4):474-485. doi: 10.1016/j.clinthera.2013.02.027 PMID: 23541130
24. Schröder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009 Sep; 9(9):1331-1339. doi: 10.1586/ern.09.81 PMID: 19769448
25. Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif. 2009; 28(2):108-115. doi: 10.1159/000224630 PMID: 19521072
26. Llufriu S, Castillo J, Blanco Y, Ramió-Torrentà L, Río J, Vallès M, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009 Sep; 73 (12):949-953. doi: 10.1212/WNL.0b013e3181b879be PMID: 19770470
27. Linker RA, Chan A, Sommer M, Koziolek M, Müller GA, Paulus W, et al. Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol. 2007 Sep; 254(9):1288-1289. PMID: 17703342
28. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul; 50(1):121-127. PMID: 11456302
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 Nov; 33(11):1444-1452. PMID: 6685237
30. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 2010 Jul; 3(4):229-239. doi: 10.1177/1756285610374117 PMID: 21179614
31. Hommes OR, Sørensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004 Sep; 364(9440):1149-1156. PMID: 15451222
32. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004 Apr; 55(4):458-468. PMID: 15048884
33. Sastre-Garriga J, Tintoré M, Rovira A, Grivé E, Pericot I, Comabella M, et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler. 2003 Feb; 9(1):39-43. PMID: 12617267
34. Sprenger KB, Huber K, Kratz W, Henze E. Nomograms for the prediction of patient's plasma volume in plasma exchange therapy from height, weight, and hematocrit. J Clin Apher. 1987; 3(3):185-190. PMID: 3558344
35. Kaplan AA. Toward the Rational Prescription of Therapeutic Plasma Exchange: The Kinetics of Immunoglobulin Removal. Semin Dial. 1992; 5:227-229
36. Dau PC, Petajan JH, Johnson KP, Panitch HS, Bornstein MB. Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 1980 Oct; 30(10):1023-1028. PMID: 6448360
37. Weiner HL, Dawson DM. Plasmapheresis in multiple sclerosis: preliminary study. Neurology 1980 Oct; 30(10):1029-1033. PMID: 7191492
38. Bramlage CP, Schröder K, Bramlage P, Ahrens K, Zapf A, Müller GA, et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher. 2009; 24(6):225-231. doi: 10.1002/jca.20217 PMID: 19890911
39. Kaplan A. Complications of apheresis. Semin Dial. 2012 Mar-Apr; 25(2):152-158. doi: 10.1111/j.1525-139X.2011.01026.x PMID: 22321209
40. Khatri BO. Therapeutic apheresis in multiple sclerosis and other central nervous system disorders. Ther Apher. 2000 Aug; 4(4):263-270. PMID: 10975471
41. Selmi C, Mix E, Zettl UK. A clear look at the neuroimmunology of multiple sclerosis and beyond. Autoimmun Rev. 2012 Jan; 11(3):159-162. doi: 10.1016/j.autrev.2011.05.006 PMID: 21624507
42. McLeod BC. Plasmapheresis in multiple sclerosis. J Clin Apher. 2003; 18(2):72-74. PMID: 12874820
43. Keegan M, König F, McClelland R, Brück W, Morales Y, Bitsch A, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005 Aug 13-19; 366 (9485):579-582. PMID: 16099294
44. Matzke B, Metze C, Winkelmann A, Grossmann A, Hartung HP, Benecke R, et al. Severe relapse of multiple sclerosis during plasma exchange treatment. Mult Scler. 2011 Jun; 17(6):759-762. doi: 10.1177/1352458511401461 PMID: 21427132
45. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr; 46(4):907-911. PMID: 8780061
46. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003 Dec 9; 61(11):1528-1532. PMID: 14663037
47. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991 Feb 23; 337 (8739):441-446. PMID: 1671468